Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders

Journal article

Background People with haematological disorders are frequently at risk of severe or life‐threatening bleeding as a result of thrombocytopenia (reduced platelet count). This is despite the routine use of prophylactic platelet transfusions to prevent bleeding once the platelet count falls below a certain threshold. Platelet transfusions are not without risk and adverse events may be life‐threatening. A possible adjunct to prophylactic platelet transfusions is the use of ant...

Expand abstract

Authors: Estcourt, LJ; Desborough, M; Brunskill, SJ; Doree, C; Hopewell, S

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Cochrane Collaboration
• Journal: Cochrane Database of Systematic Reviews
• Volume: 2016
• Issue: 3
• Article number: CD009733
• Publication date: 2016-03-15
• DOI: 10.1002/14651858.CD009733.pub3
• ISSN: 1469-493X
• Language: English
• Subjects: Antifibrinolytic Agents [∗therapeutic use]; Erythrocyte Transfusion [utilization]; Hematologic Diseases [∗complications; drug therapy]; Aminocaproic Acid [∗therapeutic use]; Thrombocytopenia [etiology; therapy]; Platelet Transfusion [adverse effects]; Lysine [analogs and derivatives]; Tranexamic Acid [∗therapeutic use]; Hemorrhage [etiology; ∗prevention and control]